Search

Maftivimab

[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. … All three mAbs bind to a distinct portion of the GP_1,2 glycoprotein and collectively provide neutralizing and Fc-mediated immune effector function against EBOV _in vitro_ and protection against

Chlormadinone acetate

Chlormadinone acetate is a progesterone derivative first synthesized in 1961. … In the US, chlormadinone acetate was formerly marketed as a component of the combination drug products Estalor-21 and C-Quens.

Lumasiran

Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). … [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation.

Berotralstat

Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE).

Nitric acid

Rurioctocog alfa pegol

[L40119] Rurioctocog alfa pegol is a covalent conjugate of [octocog alfa], which is a recombinant factor VIII produced by recombinant DNA technology from a Chinese hamster ovary cell line. … Bleeding in joints is a common manifestation of hemophilia A, and bleeding episodes can be severe and life-threatening like intracranial hemorrhage.

Inodiftagene vixteplasmid

Inodiftagene vixteplasmid is a plasmid DNA vector encoding the diphtheria toxin A (dT-a) gene under transcriptional regulation of the promoter region of the human H19 gene (an imprinted maternally expressed

Ilacirnon

Ilacirnon (CCX-140) is under investigation in clinical trial NCT01440257 (A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria).

ORP-101

ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).

Acrizanib

Acrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).